作者
Francesca Puledda,Simona Sacco,Hans‐Christoph Diener,Messoud Ashina,Haidar Muhsen Al-Khazali,Sait Ashina,Sait Ashina,Eric Liebler,Andrea Cipriani,Min Kyung Chu,Alexandra Cocores,Freda Dodd-Glover,Esme Ekizoğlu,David García‐Azorín,Hartmut Göbel,Maria Terésa Goicochea,Amr Hassan,Koichi Hirata,Jan Hoffmann,Bronwyn Jenkins,Katharina Kamm,Mi Ji Lee,Yu‐Hsiang Ling,Marco Lisicki,Daniele Martinelli,Teshamae Monteith,Raffaele Ornello,Aynur Özge,Todd D. Rozen,Patricia Pozo‐Rosich,V.I. Romanenko,Todd J. Schwedt,Marcio Nattan Portes Souza,Tsubasa Takizawa,Gisela M. Terwindt,Janu Thuraiaiyah,Mansoureh Togha,Nicolas Vandenbussche,Shuu‐Jiun Wang,Shengyuan Yu,Cristina Tassorelli
摘要
Background In an effort to improve migraine management around the world, the International Headache Society (IHS) has here developed a list of practical recommendations for the acute pharmacological treatment of migraine. The recommendations are categorized into optimal and essential, in order to provide treatment options for all possible settings, including those with limited access to migraine medications. Methods An IHS steering committee developed a list of clinical questions based on practical issues in the management of migraine. A selected group of international senior and junior headache experts developed the recommendations, following expert consensus and the review of available national and international headache guidelines and guidance documents. Following the initial search, a bibliography of twenty-one national and international guidelines was created and reviewed by the working group. Results A total of seventeen questions addressing different aspects of acute migraine treatment have been outlined. For each of them we provide an optimal recommendation, to be used whenever possible, and an essential recommendation to be used when the optimal level cannot be attained. Conclusion Adoption of these international recommendations will improve the quality of acute migraine treatment around the world, even where pharmacological options remain limited.